Skip to main content

Table 1 Patient characteristics

From: Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

No. of patients

11

 

Gender (%)

 Male

8

(72.7)

 Female

3

(27.3)

Age (years)

 Median (range)

72

(56–84)

ECOG performance status (%)

 0

4

(36.4)

 1

6

(54.5)

 2

1

(9.1)

Smoking status (%)

 Never

4

(36.4)

 Ex/current

7

(63.6)

Asbestos inhalation history (%)

 + 

6

(54.5)

 − 

5

(45.5)

Histology (%)

 Epithelial type

11

(100.0)

1st line regimen

 CDDP + PEM

5

(45.5)

 CBDCA + PEM

6

(54.5)

Regimen line (%)

 2nd

10

(90.9)

 3rd

1

(9.1)

  1. CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin